RECORLEV: payments to doctors
Payments that named RECORLEV as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.3M
- Providers
- 5,782
- Transactions
- 21,416
- Average per transaction
- $62
The per-transaction average — $62 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,782 providers the average total is $229, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | $1,321,526 | 100.0% |